Article info

Extended report
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

Authors

  1. Correspondence to Dr Eustratios Bananis, US Medical Affairs, Inflammation & Immunology, Global Innovative Pharma, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA; stratis.bananis{at}pfizer.com
View Full Text

Citation

Charles-Schoeman C, Burmester G, Nash P, et al
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

Publication history

  • Received December 18, 2014
  • Revised June 24, 2015
  • Accepted July 14, 2015
  • First published August 14, 2015.
Online issue publication 
June 10, 2016

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.